Evidence review

Sermorelin: A Growth-Hormone Secretagogue With a Narrow Approved History

Sermorelin is a synthetic fragment of growth-hormone-releasing hormone. It previously held FDA approval for paediatric growth-hormone deficiency diagnosis and treatment;

What it is and what it does

Sermorelin is a 29-amino-acid fragment of growth-hormone-releasing hormone. It stimulates the pituitary to release growth hormone rather than supplying growth hormone directly, which is the basis of the argument that it is more physiological than exogenous HGH — the pituitary's own feedback loops remain in play.

That mechanism is real. Sermorelin does raise growth hormone and IGF-1 in people whose pituitary can respond, and that is measurable.

The regulatory history matters here

Sermorelin previously held FDA approval, used in paediatric growth-hormone deficiency. The branded product was withdrawn from the US market, and the withdrawal was commercial rather than a safety action — a distinction that matters, because a drug withdrawn for safety and a drug withdrawn for economics are very different situations.

What follows is that sermorelin now reaches patients through compounding rather than as an approved product. That places it inside the regulatory system when prescribed and dispensed properly, and it means no current product has been through premarket review.

Where this sits on the evidence ladder

We grade every claim in this category against four tiers, because collapsing them is how peptide marketing works.

Tier 1 — approved drug. Premarket review of safety, effectiveness and manufacturing quality. A registry number and a peer-reviewed publication behind each indication.

Tier 2 — human randomised trials, hard endpoints. Not approved for the marketed use, but tested in people against a comparator on something a patient would notice.

Tier 3 — human data without controls. Open-label series, biomarker studies, small uncontrolled cohorts. Useful for generating hypotheses, unreliable for estimating effect.

Tier 4 — animal and mechanistic work. Where most peptide marketing draws its citations. The attrition rate between promising rodent data and demonstrated human benefit is very high across all of pharmacology.

Where sermorelin actually sits

Tier 3, mostly, for the uses it is marketed for. The endocrine effect — raised GH and IGF-1 — is Tier 2 or better and is not really disputed. The claims built on top of it are the problem.

Improved body composition, sleep quality, recovery, skin, energy and healthspan are the marketed outcomes. What exists for those is mechanistic reasoning, biomarker change, and testimonial. What does not exist is a body of randomised trials in healthy adults showing durable functional benefit against a comparator.

Raising a hormone is target engagement. It is the same category of finding as raising blood NAD+ levels, and it carries the same caution: engagement without demonstrated outcome is the most common result in translational research.

The safety questions worth asking

Growth hormone axis manipulation is not risk-free. IGF-1 elevation has a complicated relationship with cancer risk in the epidemiological literature, glucose tolerance can worsen, and the long-term consequences of sustained secretagogue use in healthy adults have not been characterised because nobody has run that trial.

Anyone prescribing this should be checking IGF-1 and glucose, and should be able to say what level would make them stop. If those questions produce a vague answer, that is informative.

Practical questions before starting

1. Which pharmacy compounds this, and under which registration?
2. What baseline bloods are taken, and what is monitored during treatment?
3. What IGF-1 level would make you reduce or stop?
4. What human trial supports the specific outcome I am being sold?

Questions readers actually ask